Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry

John Tesser1 · Iris Lin2 · Natalie J. Shiff2,3 · Soumya D. Chakravarty2,4 · Gabriela Schmajuk5 · Nevin Hammam5 · Sheetal Desai6

Received: 20 December 2021 / Revised: 15 February 2022 / Accepted: 22 February 2022 / Published online: 21 March 2022 © The Author(s) 2022

Abstract
Infliximab and golimumab are intravenously (IV) administered tumor necrosis factor inhibitors approved to treat moderate-to-severe rheumatoid arthritis (RA) with concomitant methotrexate. Owing to differences in biologic construct, patients with IV-infliximab treatment failure may benefit from switching to IV-golimumab. Utilizing the ACR’s Rheumatology Informatics System for Effectiveness (RISE), a large electronic health records registry based in the USA, we assessed RA disease activity in patients switching from IV-infliximab to IV-golimumab. This retrospective, longitudinal, single-arm study included adults (≥ 18 years) with ≥ 1 RA diagnosis code between 2014 and 2018 and ≥ 1 IV-infliximab prescription within 6 months of a new IV-golimumab order (index date). Longitudinal assessments of disease activity using the Clinical Disease Activity Index (CDAI) were calculated in patients continuing IV-golimumab for 6–9- and 9–12-months post-switch. Paired t-tests evaluated significance of mean improvements during the follow-up periods. Most RA patients with disease activity assessments during the 6-month follow-up (N = 100; mean age: 65.3 years; 81% female; 74% white) demonstrated moderate-to-high disease activity (CDAI: 73% [38/52]) at enrollment. On average, patients showed significant improvement in disease activity within 6–9 months of switching; mean CDAI scores improved from 21.3 to 14.1 (p < 0.0001) and were durable through 9–12 months of treatment. Real-world patients with moderate-to-high disease activity who switched from IV-infliximab to IV-golimumab demonstrated significant and sustained improvements post-switch as measured by the CDAI.

Key Points
• This study used real-world data from the Rheumatology Informatics System for Effectiveness (RISE) registry to evaluate the efficacy of directly switching from intravenous (IV)-infliximab to IV-golimumab to control rheumatoid arthritis (RA) disease activity.
• Most IV-infliximab patients had moderate-to-high disease activity at the time of the switch.
• On average, IV-golimumab was effective in improving RA disease activity after switching from IV-infliximab as measured by the Clinical Disease Activity Index.
• These data suggest that real-world RA patients with persistent symptoms despite treatment with IV-infliximab may realize improved disease control with a switch to IV-golimumab.

A portion of these data were previously presented at the Congress of Clinical Rheumatology–West: Tesser J, Lin I, Kafka S, Schmajuk G, Hammam N, Evans M, Desai S. Improvement in disease activity among patients with rheumatoid arthritis who switched from infliximab to golimumab IV. Poster presentation at Congress of Clinical Rheumatology–West, San Diego, CA: October 1–3, 2020.

John Tesser
jtesser1@cox.net

1 Arizona Arthritis & Rheumatology Associates, 4550 E. Bell Road, Suite 172, Phoenix, AZ 85032, USA
2 Janssen Scientific Affairs, LLC, Horsham, PA, USA
3 Adjunct, Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, SK, Canada
4 Drexel University College of Medicine, Philadelphia, PA, USA
5 University of California San Francisco, San Francisco, CA, USA
6 University of California, Irvine, Irvine, CA, USA
**Keywords**  Rheumatoid arthritis · Intravenous golimumab · Intravenous infliximab · Tumor necrosis factor · Disease activity · Registry

### Introduction

Golimumab, a fully human monoclonal antibody administered intravenously (IV) or subcutaneously [1, 2], and IV-infliximab, a chimeric monoclonal antibody [3], are tumor necrosis factor inhibitors (TNFi). TNFi are biologic disease-modifying anti-rheumatic drugs (bDMARDs) approved to treat moderate-to-severe rheumatoid arthritis (RA). IV-infliximab and IV-golimumab are both approved for use in combination with methotrexate (MTX). IV-golimumab and IV-infliximab safety and efficacy in RA patients are well characterized across multiple clinical trials [4–9]. Individual clinical trial data, though not from a head-to-head phase 3 study, suggest similar efficacy with these IV TNFi [4–9]. Conversely, these agents differ with respect to the reported incidence of certain adverse reactions [10, 11]. RA patients commonly switch to a different TNFi after initial course failure. Although data from one randomized controlled trial supporting TNFi switching are acknowledged [12], other data are lacking.

The Rheumatology Informatics System for Effectiveness (RISE) registry is a Health Insurance Portability and Accountability Act-compliant, Qualified Clinical Data Registry developed by the American College of Rheumatology (ACR) to passively collect electronic health record data for clinicians and researchers [13]. Using real-world data from RISE, this study evaluated the efficacy of switching from IV-infliximab to IV-golimumab to control RA disease activity.

### Patients and methods

#### Study design and data source

This retrospective, longitudinal, single-arm study (Fig. 1) was conducted using data from the RISE registry. RISE contains data collected during routine clinical care, primarily in private rheumatology practices in the United States (US). Data contribution began in January 2014 and included patient demographics, diagnoses, procedures, medications, laboratory test results, RA disease activity scores, and vital signs. In 2018, the database held records from 1113 providers (226 practices accounting for ~30% of the US rheumatology clinical workforce) and 1.6 million patients. This study was approved by a central Institutional Review Board (Western IRB) and the University of California at San Francisco (UCSF) IRB.

#### Patient population

Adults (≥ 18 years of age) in this study had ≥ 1 International Classification of Diseases (ICD) RA diagnosis code (ICD-9-code: 714.*, ICD-10-codes: M05.*, M06.*, excluding M06.4 [inflammatory polyarthropathy]) between 2014 and 2018, ≥ 1 recorded IV-infliximab prescription within 6 months of “new” IV-golimumab use, and a rheumatoid arthritis disease activity (RADA) measure both at baseline and at least once during the follow-up periods (Fig. 2).

![Fig. 1](https://example.com/f1.png)  
**Fig. 1** Study design for efficacy evaluation of switching from IV-infliximab to IV-golimumab in controlling RA disease. All medication use was reported from patient medication reconciliation, e-prescription, or procedure (medication administration) tables. aContinued IV-golimumab use, with no gaps in treatment, was required for 6–9 months after the index date for the 6-month follow-up. bContinued IV-golimumab use, with no gaps in treatment, was required for 9–12 months after the index date for the 9-month follow-up. IV, intravenous; RA, rheumatoid arthritis; RADA, rheumatoid arthritis disease activity; SC, subcutaneous.
The index date was defined as the date the medication first appeared in the patient medication reconciliation, e-prescription, or procedure (medication administration) tables (see “7” section, below). The baseline RADA must have been completed between 90 days prior to and up to 30 days after the index date. “New” use was defined as no IV-golimumab within 12 months prior to the index date. Continued IV-golimumab use, with no gaps in treatment, was required for 6–9 months after the index date (6-month follow-up) and for 9–12 months after the index date (9-month follow-up) for patient inclusion in respective analyses. A treatment gap was defined as ≥ 4 weeks between actual and planned IV-golimumab prescription based on every-8-week administration per the approved dosing regimen. A sensitivity analysis of disease activity for the 6-month follow-up included all patients with a RADA at baseline and allowed gaps of ≥ 4 weeks. This study included all patients with index dates between January 1, 2014, and June 30, 2018, and used data available until December 31, 2018, to allow for sufficient follow-up time. Follow-up time was the period between a patient’s first and most recent face-to-face visits with the rheumatologist. Patients with ≥ 2 ICD codes for systemic lupus erythematosus, psoriatic arthritis, scleroderma, inflammatory bowel disease, or sarcoidosis at any time pre-index date or during the 6- or 9-month follow-up periods were excluded, ensuring study participants were prescribed IV-golimumab to treat RA only. Patients who had recorded use of any other biologics or tofacitinib within 6 months prior to the index date or 6-9 months after the index date for 6-month and 9-month follow-up analyses, respectively, were excluded, as were pregnant women.

**Fig. 2** Study patient profile. All medication use was reported from patient medication reconciliation, e-prescription, or procedure (medication administration) tables. *Date IV-golimumab medication first appeared in the patient medication reconciliation, e-prescription, or procedure (medication administration) tables. **Continued IV-golimumab use, with no gaps in treatment, was required for 6–9 months after the index date for the 6-month follow-up. *Continued IV-golimumab use, with no gaps in treatment, was required for 9–12 months after the index date for the 9-month follow-up. IV, intravenous; RA, rheumatoid arthritis; RADA, rheumatoid arthritis disease activity; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.
Sociodemographic variables

Baseline demographics including age, sex, race, ethnicity, geographic regions, insurance type, and rheumatology practice type were assessed within 12 months prior to the index date. Geographic regions were defined according to the US Census.

Clinical and laboratory variables

Charlson comorbidity index scores were calculated, based on single ICD-9 and ICD-10 codes within 12 months prior to the index date, according to the Deyo modification [14, 15]; body mass index (BMI) was also reported during this timeframe. Serum C-reactive protein concentration and erythrocyte sedimentation rate within 3 months prior to the index date were reported.

Medication exposure

Medication information, including concomitant medication use, was derived from patient reports during face-to-face visits in all practices; e-prescription data sent electronically from provider to pharmacy in ~20% of practices; and, in a minority of cases, procedure (administration) codes. The number of IV-infliximab prescriptions within 6 months prior to the index date and the number of days separating the most recent IV-infliximab prescription and the index date were reported. The cumulative dose of IV-infliximab prescribed within 6 months prior to the index date was calculated from the medication administration description field text, where available, by one of two methods:

\[
\text{infliximab dose} \left( \frac{mg}{kg} \right) \times \text{patient weight (kg)} \times \text{number of infliximab doses}
\]

\[
\text{infliximab dose} \left( \frac{mg}{dose} \right) \times \text{number of infliximab doses}
\]

Patients were considered to have received a prior biologic or targeted synthetic DMARD if they had recorded prescription of ≥1 of the following drugs within 6–12 months prior to the index date: abatacept, adalimumab, certolizumab, etanercept, infliximab, rituximab, tocilizumab, or tofacitinib.

Outcome measures

RA disease activity was primarily assessed using the Clinical Disease Activity Index (CDAI) at baseline (-90 to +30 days of index date) and during the 6- or 9-month follow-up period post-switch to IV-golimumab. For these periods, respectively, any assessment available between 6–9 and 9–12 months after the index date was eligible for analysis. If multiple assessments were available for these periods, those closest to 6–9 months after the index dates were analyzed. The CDAI sums the swollen (0–28) and tender (0–28) joint counts and the rating of global disease activity (0–10) provided by the physician and patient [16]. The Routine Assessment of Patient Index Data 3 (RAPID3), a patient-reported outcome measure without formal joint counts that consists of the Multidimensional Health Assessment Questionnaire patient self-report RA Core Data Set measures for physical function, pain, and patient global estimate (score range: 0–30) [17], was also documented in some settings.

Statistical analyses

Observed data were summarized with parametric and non-parametric descriptive statistics as appropriate. CDAI scores were reported as mean absolute scores and by categories of disease activity (remission/low/moderate/high) as recommended by ACR [18]. Changes in CDAI scores from baseline were assessed using paired t-tests. Shifts in patient distributions across disease activity categories were assessed using one-way repeated measures ANOVA. RAPID3 data were similarly summarized. Statistical testing was two-sided, with a significance level of <0.05. Analyses were performed using Stata Statistical Software (Release 15; StataCorp, LLC; College Station, TX).

Results

Patient disposition and baseline characteristics

Among eligible patients with a baseline and follow-up RADA measure, 100 (52 with CDAI data) and 63 (32 with CDAI data) reported IV-golimumab persistence for ≥6 and ≥9 months, respectively; patients with and without recorded CDAI data were generally similar (Table 1); sensitivity analyses allowing treatment gaps ≥4 weeks included 146 patients (81 with CDAI data; Online Resource 1). Among the 52 patients with CDAI scores at 6-month follow-up, the mean (standard deviation [SD]) age was 64.8 (11.4) years; 81% were female, 79% were white, and 38% were privately insured. On average, patients were followed for 75 months and had 3.3 rheumatology office visits within 12 months prior to the index date; 56% of patients reported receiving ≥2 IV-infliximab prescriptions within 6 months prior to the index date (average cumulative dose of 1686 mg among those with data available); and 52% were receiving concomitant MTX (Table 1). Baseline characteristics were consistent across patient cohorts with CDAI vs. RAPID3 data (data not shown) and between the 6- and 9-month follow-up cohorts (Table 1).
RA disease activity after switching from IV-infliximab to IV-golimumab

Among 52 patients with CDAI assessments, the mean (SD) CDAI score significantly improved from 21.3 (13.1) at baseline to 14.1 (9.8) during the 6-month follow-up period ($p < 0.0001$). During this timeframe, the proportion of patients with moderate/high disease activity decreased from 73 to 56%, and the proportion with low/remitted disease activity increased from 27 to 44% ($p < 0.0001$). Significant improvements from baseline in CDAI scores were also observed during the 9-month follow-up (Table 2). Similar response patterns were observed with RAPID3 assessments during the 9-month follow-up (Online Resource 2).

Sensitivity analyses of 81 patients with baseline and 6-month post-switch CDAI scores, regardless of dosing interval duration of IV-golimumab, similarly showed significant mean (SD) CDAI score improvement from 19.3 (12.4) at baseline to 13.6 (10.6) during the 6-month follow-up ($p < 0.0001$). Proportions of patients with moderate/high disease activity decreased from 70 to 49%, and with low/remitted disease activity increased from 30 to 51%, during the same timeframe ($p < 0.001$; Online Resource 3).

Discussion

Treatment of RA with TNFi has proven effective after MTX/conventional synthetic DMARD combination treatment failure [19]. However, some patients treated with TNFi fail to achieve low disease activity, lose response over time, or experience adverse events, often prompting a dose increase, switch to a different TNFi, or switch to a biologic with a different mechanism of action. Potential neutralizing anti-drug antibody formation [10] and infusion reactions can reduce efficacy and limit therapeutic effect in ~25% of patients receiving IV-infliximab [11]. Such patients may benefit from switching to a fully human biologic, such as IV-golimumab, to control disease activity/improve drug tolerance. IV-golimumab has demonstrated long-term benefit in reducing RA signs and symptoms and improving physical function and is well-tolerated by patients [5]. IV-golimumab is less immunogenic than other TNFi [20]. Using data from the real-world RISE registry, we compared disease activity before and after direct switching from IV-infliximab to IV-golimumab in RA patients.

Patients switching from IV-infliximab to IV-golimumab generally had moderate-to-high disease activity at the time of IV-golimumab initiation. Of note, 44% received <2 IV-infliximab doses during the 6 months prior to switching, potentially indicating under-treated disease, as maintenance treatment is usually given every 8 weeks. Reasons for the low number of doses were not captured (such as prior ineffectiveness, intolerance, insurance coverage). Significantly improved disease activity with $\geq 6$ and $\geq 9$ months of persistent IV-golimumab use post-switch may support the clinical benefit of this treatment approach among patients whose disease is inadequately controlled with IV-infliximab. Specifically, mean CDAI scores decreased by ~35% and ~30% at 6- and 9-month follow-ups, translating into almost 20% of patients shifting from moderate/high to low/remitted disease activity after switching to IV-golimumab. Statistical findings with the RAPID3 assessment were inconsistent between the 6- and 9-month follow-ups. A previous report indicates that, except for the patient global assessment, CDAI and RAPID3 components are not highly correlated [21]. The discordance of group-level data in this study is consistent with a previous IV-infliximab-to-IV-golimumab switch study [22] and is likely due to the exclusively patient-reported components that compose the RAPID3 score that may be conflated by other factors including anxiety, depression, and pain catastrophizing [17, 23, 24]. The CDAI, on the other hand, comprises a physician-reported scale plus a patient global score and total tender and swollen joint counts [16]; evidence points to tender and swollen joint counts as being the main CDAI score contributors [25].

Limitations

The primary analysis included only patients who persistently used IV-golimumab during the 6- and 9-month follow-up periods, potentially introducing responder/selection bias. As a single-arm longitudinal study, confounding by indication is possible. These analyses are not comprehensive of patients’ reason(s) for switching from IV-infliximab, length of time on IV-infliximab, or dose escalation/de-escalation. Sample size was relatively small, and stratification of patients by full IV-infliximab history was therefore not possible. Follow-up was also relatively short for RA. A small number of RA patients also had ankylosing spondylitis, though the proportion was similar across follow-up and sensitivity analysis cohorts ($\leq 5\%$). Despite these limitations, these real-world patients with moderate-to-high disease activity appeared to benefit from switching to IV-golimumab. Studies of longer duration will be needed to assess long-term effectiveness of IV-golimumab in these patients.

Conclusion

Results of this study using RISE data suggest that IV-golimumab is effective in improving RA disease activity in a patient population switching directly from IV-infliximab, as measured by the CDAI, a standard disease activity index aligned with ACR and EULAR treat-to-target guidelines. Given the limited real-world data documenting efficacy of
Table 1  Baseline characteristics of RA patients who switched from IV-infliximab to IV-golimumab with data available for 6-month (6–9 months after switch) and 9-month (9–12 months after switch) follow-up analyses who had any RADA score (CDAI or RAPID3), and with data available for 6-month and 9-month follow-up analyses who had a CDAI score only

| Variables                                      | 6-month follow-up | CDAI (N=52) | 9-month follow-up | CDAI (N=32) |
|------------------------------------------------|-------------------|-------------|-------------------|-------------|
| Age (years), mean (SD)                         | 65.3 (11.4)       | 64.8 (11.4) | 67.1 (11.0)       | 66.9 (10.4) |
| Female, n (%)                                  | 81 (81.0)         | 42 (80.8)   | 52 (82.5)         | 26 (81.2)   |
| Race and ethnicity, n (%)                      |                   |             |                   |             |
| White (non-Hispanic)                           | 74 (74.0)         | 41 (78.8)   | 44 (69.8)         | 23 (71.9)   |
| Asian                                          | 4 (4.0)           | 1 (1.9)     | 1 (1.6)           | 0 (0.0)     |
| Black or African American                      | 3 (3.0)           | 2 (3.8)     | 6 (9.5)           | 4 (12.5)    |
| Others\textsuperscript{a}                      | 7 (7.0)           | 5 (9.6)     | 4 (6.3)           | 2 (6.2)     |
| Missing                                        | 8 (8.0)           | 0 (0.0)     | 7 (11.1)          | 2 (6.2)     |
| Hispanic or Latino                             | 4 (4.0)           | 3 (5.8)     | 1 (1.6)           | 1 (3.1)     |
| Insurance, n (%)                               |                   |             |                   |             |
| Medicare                                       | 42 (42.0)         | 22 (42.2)   | 27 (42.9)         | 16 (50.0)   |
| Medicaid                                       | 8 (8.0)           | 5 (9.6)     | 8 (12.7)          | 7 (21.9)    |
| Private                                        | 37 (37.0)         | 20 (38.5)   | 20 (31.8)         | 7 (21.9)    |
| Other                                          | 2 (2.0)           | 2 (3.8)     | 2 (3.2)           | 1 (3.1)     |
| Missing                                        | 11 (11.0)         | 3 (5.8)     | 6 (9.5)           | 1 (3.1)     |
| US geographic divisions, n (%)                 |                   |             |                   |             |
| New England                                    | 0 (0.0)           | 0 (0.0)     | 0 (0.0)           | 0 (0.0)     |
| Mid-Atlantic                                    | 6 (6.0)           | 2 (3.8)     | 4 (6.4)           | 2 (6.2)     |
| East North Central                              | 25 (25.0)         | 17 (32.7)   | 16 (25.4)         | 12 (37.5)   |
| West North Central                              | 5 (5.0)           | 1 (1.9)     | 5 (7.9)           | 0 (0.0)     |
| South Atlantic                                  | 34 (34.0)         | 15 (28.8)   | 26 (41.3)         | 9 (28.1)    |
| East South Central                              | 6 (6.0)           | 2 (3.8)     | 0 (0.0)           | 0 (0.0)     |
| West South Central                              | 7 (7.0)           | 3 (5.8)     | 2 (3.2)           | 2 (6.2)     |
| Mountain                                        | 5 (5.0)           | 5 (9.6)     | 4 (6.4)           | 4 (12.5)    |
| Pacific                                        | 12 (12.0)         | 7 (13.5)    | 6 (9.5)           | 3 (9.4)     |
| Practice types, n (%)                           |                   |             |                   |             |
| Single specialty group                          | 63 (63.0)         | 32 (61.5)   | 45 (71.4)         | 20 (62.5)   |
| Multi-specialty Group                          | 29 (29.0)         | 19 (36.5)   | 16 (25.4)         | 12 (37.5)   |
| Solo practitioner                               | 3 (3.0)           | 0 (0.0)     | 0 (0.0)           | 0 (0.0)     |
| Other clinical settings                         | 5 (5.0)           | 1 (1.9)     | 2 (3.2)           | 0 (0.0)     |
| Months of follow-up, mean (SD)                 | 69.0 (25.6)       | 74.9 (29.0) | 71.3 (24.7)       | 75.6 (29.0) |
| Number of visits\textsuperscript{b}, mean (SD) | 3.5 (1.4)         | 3.3 (1.1)   | 3.4 (1.3)         | 3.3 (1.3)   |
| BMI n (%) patients with data                    | 84 (84.0)         | 45 (86.5)   | 53 (84.1)         | 25 (78.1)   |
| Mean (SD)                                       | 30.2 (8.2)        | 31.5 (8.8)  | 29.9 (6.9)        | 30.5 (7.8)  |
| Charlson comorbidity index n (%) patients with data | 86 (86.0)     | 46 (88.5)   | 54 (85.7)         | 28 (87.5)   |
| Mean (SD)                                       | 1.7 (1.3)         | 1.8 (1.4)   | 1.9 (1.7)         | 2.4 (2.1)   |
| Laboratory measures within 3 months prior to the index date | | | |
| ESR, mm/h n (%) patients with data              | 59 (59.0)         | 33 (63.5)   | 35 (55.6)         | 15 (46.9)   |
| Mean (SD)                                       | 26.6 (23.2)       | 25.2 (22.1) | 27.9 (23.4)       | 35.4 (30.5) |
| CRP, mg/dL n (%) patients with data             | 59 (59.0)         | 30 (57.7)   | 39 (61.9)         | 17 (53.1)   |
| Mean (SD)                                       | 2.4 (4.5)         | 3.6 (9.9)   | 2.6 (5.1)         | 1.7 (3.0)   |
| Prior bDMARD use\textsuperscript{d}, n (%)     |                   |             |                   |             |
| Adalimumab                                      | 2 (2.0)           | 1 (1.9)     | 2 (3.2)           | 1 (3.1)     |
| Etanercept                                      | 0 (0.0)           | 0 (0.0)     | 0 (0.0)           | 0 (0.0)     |
| Certolizumab                                    | 0 (0.0)           | 0 (0.0)     | 0 (0.0)           | 0 (0.0)     |
| Abatacept                                       | 1 (1.0)           | 1 (1.9)     | 1 (1.6)           | 0 (0.0)     |
| Rituximab                                       | 1 (1.0)           | 0 (0.0)     | 1 (1.6)           | 0 (0.0)     |
| Tocilizumab                                     | 1 (1.0)           | 1 (1.9)     | 1 (1.6)           | 1 (3.1)     |
| Prior tsDMARD use\textsuperscript{d}, n (%)    |                   |             |                   |             |
| Tofacitinib                                     | 2 (2.0)           | 1 (1.9)     | 0 (0.0)           | 0 (0.0)     |
| Average number of IV-infliximab prescriptions (within 6 months prior to the index date), mean (SD) | 1.6 (0.7) | 1.7 (0.8) | 1.6 (0.7) | 1.6 (0.8) |
Table 1 (continued)

| Variables                                                                 | 6-month follow-up | 9-month follow-up |
|---------------------------------------------------------------------------|-------------------|-------------------|
|                                                                           | Any RADA (N=100)  | CDAI (N=52)       | Any RADA (N=63)  | CDAI (N=32)       |
| Days between last IV-infliximab prescription and index date, mean (SD)    | 43.5 (17.2)       | 42.9 (20.0)       | 44.6 (19.7)       | 45.8 (24.7)       |
| Number of IV-infliximab prescriptions reported by n (%) patients within 6 months prior to the index date |                   |                   |                   |                   |
| 1                                                                         | 43 (43.0)         | 23 (44.2)         | 30 (47.6)         | 16 (50.0)         |
| 2                                                                         | 23 (23.0)         | 8 (15.4)          | 10 (15.9)         | 5 (15.6)          |
| 3                                                                         | 19 (19.0)         | 12 (23.1)         | 15 (23.8)         | 6 (18.8)          |
| 4                                                                         | 9 (9.0)           | 4 (7.7)           | 4 (6.4)           | 2 (6.2)           |
| >4                                                                        | 6 (6.0)           | 5 (9.6)           | 4 (6.4)           | 3 (9.4)           |
| Total IV-infliximab dose reported within 6 months prior to the index date (mg) n (%) patients with data |                   |                   |                   |                   |
| Mean (SD)                                                                 | 1737.2 (1065.5)   | 1685.8 (1289.3)   | 1723.5 (1038.3)   | 1661.4 (1302.6)   |
| Concomitant rheumatologic medication usee, n (%)                          |                   |                   |                   |                   |
| Systemic glucocorticoids                                                 | 61 (61.0)         | 37 (71.2)         | 39 (61.9)         | 22 (68.8)         |
| Methotrexate                                                             | 42 (42.0)         | 27 (51.9)         | 25 (39.7)         | 12 (37.5)         |
| Hydroxychloroquine                                                       | 17 (17.0)         | 9 (17.3)          | 9 (14.3)          | 3 (9.4)           |
| Leflunomide                                                              | 19 (19.0)         | 9 (17.3)          | 11 (17.5)         | 6 (18.8)          |
| Azathioprine                                                             | 4 (4.0)           | 3 (5.8)           | 5 (7.9)           | 4 (12.5)          |
| Sulfasalazine                                                            | 8 (8.0)           | 3 (5.8)           | 6 (9.5)           | 2 (6.2)           |

aOthers race: Native Hawaiian or other Pacific Islander, American Indian or Alaska Native, and multi-racial
bNumber of visits with the rheumatologist in the 12 months prior to the index date
cCharlson comorbidity index was calculated during the 12 months prior to the index date
dPrior b/tsDMARD use defined as reported use 12 to 6 months prior to the index date
eConcomitant rheumatologic medication use was defined as any other reported drug use on or after the index date and while the patient was still receiving IV-golimumab

bDMARD biologic disease-modifying antirheumatic drug, BMI body mass index, CDAI Clinical Disease Activity Index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, IV intravenous, RA rheumatoid arthritis, RADA rheumatoid arthritis disease activity, RAPID3 Routine Assessment of Patient Index Data 3, SD standard deviation, tsDMARD targeted synthetic disease-modifying antirheumatic drug, US United States

Table 2 Mean CDAI scores and categories of disease activity for RA patients with persistent IV-golimumab use during the 6-montha and 9-monthb follow-up periods

| N=52 | 6-month follow-upa | p value | N=32 | 9-month follow-upb | p value |
|------|--------------------|---------|------|--------------------|---------|
|      | Baseline | 14.1 (9.8) | <0.0001c | Baseline | 15.2 (14.1) | 0.0002c |
| Mean score (SD) | 21.3 (13.1) |
| Disease activity categoriesd, n (%) | 22.2 (13.9) |
| Remission | 0 (0.0) | 2 (3.8) | <0.001c | 0 (0.0) | 4 (12.5) | <0.001c |
| Low | 14 (26.9) | 21 (40.4) | 7 (21.9) | 13 (40.6) |
| Moderate | 16 (30.8) | 20 (38.5) | 10 (31.2) | 6 (18.8) |
| High | 22 (42.3) | 9 (17.3) | 15 (46.9) | 9 (28.1) |

aDisease activity was assessed 6–9 months after the index date
bDisease activity was assessed 9–12 months after the index date
cCalculated using a paired t-test
dCDAI sums the number of swollen (0–28) and tender (0–28) joints and the rating of global disease activity (0–10) provided by the physician and patient. Scores range from 0 to 76; scores of ≤2.8, >2.8–10.0, >10.0–22.0, and >22.0 represent remission, low, moderate, or high disease activity, respectively[16, 17]
eCalculated using a one-way repeated measures ANOVA test

CDAI clinical disease activity index, IV intravenous, RA rheumatoid arthritis, SD standard deviation
IV-infliximab-to-IV-golimumab switching, these results are clinically meaningful and may assist clinicians in providing patients with improved and sustained outcomes.

Disclaimer

This analysis was supported by the American College of Rheumatology’s Rheumatology Informatics System for Effectiveness Registry. However, the views expressed represent those of the authors, not necessarily those of the American College of Rheumatology.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10067-022-06116-z.

Acknowledgements The authors would like to thank Shelly Kafka, MD (formerly employed by Janssen), for her contributions to the study design and interpretation; Sean Quinn for administrative support of this manuscript; and Alexandra Guffey, MS for editorial support (both Janssen employees).

Author contribution Substantial intellectual contributions to study conception and design (IL, GS, NH, SD), acquisition of data (GS, NH, SD), or analysis and interpretation of data (JT, IL, NS, SDC, GS, NH, SD); drafting the article or revising it critically for important intellectual content (JT, IL, NS, SDC, GS, NH, SD); final approval of the version to be published (JT, IL, NS, SDC, GS, NH, SD); and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved (JT, IL, NS, SDC, GS, NH, SD).

Funding This analysis was funded by Janssen Research & Development, LLC, and was executed by University of California San Francisco.

Data availability The American College of Rheumatology (ACR) owns the data in the Rheumatology Informatics System for Effectiveness (RISE) registry, and University of California San Francisco, as a Data Analytic Center for the ACR, has access to the data for specific research projects, including this one, but is contractually obligated to not share this data, even in a de-identified state.

Declarations

Ethics approval A central Institutional Review Board (Western IRB) and the University of California San Francisco IRB have approved procedures for data analyses for this project.

Consent to participate Because the Rheumatology Informatics System for Effectiveness (RISE) Registry is a federally Qualified Clinical Data Registry, permissions are in place to collect data without patient informed consent for the purpose of disease tracking and quality improvement. The RISE data extraction protocol is Health Insurance Portability and Accountability Act compliant. Any RISE data used for research is analyzed only by American College of Rheumatology-contracted data analytic centers (including University of California San Francisco) and is de-identified and aggregated.

Competing interests JT has served on advisory boards/as a consultant for AbbVie, AstraZeneca, Aurinia, Bristol Myers Squibb, Janssen, Eli Lilly, Novartis, Pfizer, and Sanofi-Genzyme; served as a speaker for AbbVie, Amgen, AstraZeneca, Aurinia, Bristol Myers Squibb, Eli Lilly, Genentech, GSK, Janssen, Pfizer, and Sanofi-Genzyme; and received research grants and support from AbbVie, Amgen, AstraZeneca, Aurinia, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, CSL Behring, Eli Lilly, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Sandoz, Scipher, Takeda, Sun Pharma, UCB, Selecta, and Voro. IL, NS, and SDC are employees of Janssen Scientific Affairs, LLC, and own stock in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary of (IL, NS, SDC), AbbVie (NS), and Gilead (NS). GS is funded by AHRQ and VA IHS&RD. NH has no disclosures. SD served on speakers bureaus for AstraZeneca, Aurinia, GlaxoSmithKline, and Janssen.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Simponi: Package Insert (2019) https://www.jansslenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI-pi.pdf. Accessed 4 Dec 2021
2. Simponi ARIA: Package Insert (2021) https://www.jansslenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI-ARIA-pi.pdf. Accessed 4 Dec 2021
3. Remicade: Package Insert (2013) https://www.jansslenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf. Accessed 4 Dec 2021
4. St Clair EW, van der Heijde DFMF, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432–3443. https://doi.org/10.1002/art.20568
5. Lipsky PE, van der Heijde DFMF, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343(22):1594–1602. https://doi.org/10.1056/NEJM200011303432302
6. Weinblatt ME, Bingham CO 3rd, Mendelsohn AM et al (2013) Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 72(3):381–389. https://doi.org/10.1136/annrheumdis-2012-201411
7. Weinblatt ME, Westhovens R, Mendelsohn AM (2014) Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3 randomised multicentre double blind placebo controlled GO-FURTHER trial. Ann Rheum Dis 73(12):2152–2159. https://doi.org/10.1136/annrheumdis-2013-203742
8. Bingham CO 3rd, Mendelsohn AM, Kim L et al (2015) Maintenance of clinical and radiographic benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: week-112 efficacy and safety results of the open-label long-term extension of a phase III double-blind, randomised, placebo-controlled trial. Arthritis Care Res (Hoboken) 67(12):1627-1636. https://doi.org/10.1002/acr.22556
9. Hufnatter JE, Kafta S, Brent LH et al (2017) Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study. Curr Med Res Opin 33(4):657–666. https://doi.org/10.1080/03007995.2016.1277195
10. Wolbink GJ, Vis M, Lems W et al (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54(3):711–715. https://doi.org/10.1002/art.21671
11. Thomas SS, Borazan N, Barroso N et al (2015) Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases A systematic review and meta-analysis. BioDrugs 29(4):241–258. https://doi.org/10.1007/s40259-015-0134-5
12. Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB (2014) Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 73(12):2174–2177. https://doi.org/10.1136/annrheumdis-2014-205325
13. Yazdany J, Banshack N, Clowse M et al (2016) The Rheumatology Informatics System for Effectiveness (RISE): a national informatics-enabled registry for quality improvement. Arthritis Care Res (Hoboken) 68(12):1866–1873. https://doi.org/10.1002/acr.23089
14. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619. https://doi.org/10.1016/0895-4356(92)90133-8
15. Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130–1139. https://doi.org/10.1097/01.mlr.0000182534.19832.83
16. Aletaha D, Neil VPK, Stamm T et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7(4):R796–R806. https://doi.org/10.1186/ar1740
17. Pincus T, Swearingen CJ, Bergman M, Yazici Y (2008) RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 35(11):2136–2147. https://doi.org/10.3899/jrheum.080182
18. Anderson J, Caplan L, Yazdany J et al (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64(5):640–647. https://doi.org/10.1002/acr.21649
19. Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68(1):1–25. https://doi.org/10.1002/acr.22783
20. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C (2013) Antidrug antibodies (ADA) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72(2):165–178. https://doi.org/10.1136/annrheumdis-2012-202545
21. Kremer JM, Pappas DA, Kane K et al (2020) The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for achievement of treatment strategies. J Rheumatol 48(12):1776–1783. https://doi.org/10.3899/jrheum.200692
22. Bray VJ, Broadwell A, Baraf HSB et al (2018) The effectiveness of intravenous golimumab administered directly after infliximab in rheumatoid arthritis patients. Drugs R D 18(3):211–219. https://doi.org/10.1007/s40268-018-0240-1
23. Matcham F, Norton S, Scott DL, Steer S, Hotopf M (2016) Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology (Oxford) 55(2):268–278. https://doi.org/10.1093/rheumatology/kev306
24. Hammer HB, Uhlig T, Kvien TK, Lamp J (2018) Pain catastrophizing, subjective outcomes, and inflammatory assessments including ultrasound: results from a longitudinal study of rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 70(5):703–712. https://doi.org/10.1002/acr.23339
25. Coates LC, Merola JF, Mease PJ et al (2021) Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatology (Oxford) 60(3):1137–1147. https://doi.org/10.1093/rheumatology/keaa271

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.